inclusion criteria: * laboratory-confirmed diagnosis of sars-cov-2 pneumonia * currently hospitalized with covid-19 * symptomatic fever, cough and/or dyspnea for \< 9 days * patient or legal/authorized representative can understand and sign the study informed consent document * able to be positioned on a linear-accelerator couch for radiation therapy delivery * and at least one of the following risk factors for significant pulmonary compromise: 1. fever \> 102 degrees fahrenheit during index admission 2. respiratory rate of ≥ 26 / minute within 24 hours of screening 3. spo2 ≤ 95% on room air within 24 hours of screening 4. any patient requiring 4 l/min oxygen therapy to maintain spo2 \>93% within 24 hours of screening 5. ratio of partial pressure of arterial oxygen to fraction of inspired air \< 320. * patients may be enrolled on this trial while concurrently enrolled on other covid-19 clinical trials.

inclusion criteria: * laboratory-confirmed diagnosis of sars-cov-2 pneumonia * currently hospitalized with covid-19 * symptomatic fever, cough and/or dyspnea for \< 9 days * patient or legal/authorized representative can understand and sign the study informed consent document * able to be positioned on a linear-accelerator couch for radiation therapy delivery * and at least one of the following risk factors for significant pulmonary compromise: 1. fever \> 102 degrees fahrenheit during index admission 2. respiratory rate of ≥ 26 / minute within 24 hours of screening 3. spo2 ≤ 95% on room air within 24 hours of screening 4. any patient requiring 4 l/min oxygen therapy to maintain spo2 \>93% within 24 hours of screening 5. ratio of partial pressure of arterial oxygen to fraction of inspired air \< 320. * patients may be enrolled on this trial while concurrently enrolled on other covid-19 clinical trials.

inclusion criteria: laboratory-confirmed diagnosis of sars-cov-2 pneumonia currently hospitalized with covid-19 symptomatic fever, cough and/or dyspnea for < 9 days patient or legal/authorized representative can understand and sign the study informed consent document able to be positioned on a linear-accelerator couch for radiation therapy delivery and at least one of the following risk factors for significant pulmonary compromise: fever > 102 degrees fahrenheit during index admission respiratory rate of ≥ 26 / minute within 24 hours of screening spo2 ≤ 95% on room air within 24 hours of screening any patient requiring 4 l/min oxygen therapy to maintain spo2 >93% within 24 hours of screening ratio of partial pressure of arterial oxygen to fraction of inspired air < 320. patients may be enrolled on this trial while concurrently enrolled on other covid-19 clinical trials.

inclusion criteria: laboratory-confirmed diagnosis of sars-cov-2 pneumonia currently hospitalized with covid-19 symptomatic fever, cough and/or dyspnea for < 9 days patient or legal/authorized representative can understand and sign the study informed consent document able to be positioned on a linear-accelerator couch for radiation therapy delivery and at least one of the following risk factors for significant pulmonary compromise: fever > 102 degrees fahrenheit during index admission respiratory rate of ≥ 26 / minute within 24 hours of screening spo2 ≤ 95% on room air within 24 hours of screening any patient requiring 4 l/min oxygen therapy to maintain spo2 >93% within 24 hours of screening ratio of partial pressure of arterial oxygen to fraction of inspired air < 320. patients may be enrolled on this trial while concurrently enrolled on other covid-19 clinical trials.

inclusion criteria: - laboratory-confirmed diagnosis of sars-cov-2 pneumonia - currently hospitalized with covid-19 - symptomatic fever, cough and/or dyspnea for < 9 days - patient or legal/authorized representative can understand and sign the study informed consent document - able to be positioned on a linear-accelerator couch for radiation therapy delivery - and at least one of the following risk factors for significant pulmonary compromise: 1. fever > 102 degrees fahrenheit during index admission 2. respiratory rate of ≥ 26 / minute within 24 hours of screening 3. spo2 ≤ 95% on room air within 24 hours of screening 4. any patient requiring 4 l/min oxygen therapy to maintain spo2 >93% within 24 hours of screening 5. ratio of partial pressure of arterial oxygen to fraction of inspired air < 320. - patients may be enrolled on this trial while concurrently enrolled on other covid-19 clinical trials.

inclusion criteria: - laboratory-confirmed diagnosis of sars-cov-2 pneumonia - currently hospitalized with covid-19 - symptomatic fever, cough and/or dyspnea for < 9 days - patient or legal/authorized representative can understand and sign the study informed consent document - able to be positioned on a linear-accelerator couch for radiation therapy delivery - and at least one of the following risk factors for significant pulmonary compromise: 1. fever > 102 degrees fahrenheit during index admission 2. respiratory rate of ≥ 26 / minute within 24 hours of screening 3. spo2 ≤ 95% on room air within 24 hours of screening 4. any patient requiring 4 l/min oxygen therapy to maintain spo2 >93% within 24 hours of screening 5. ratio of partial pressure of arterial oxygen to fraction of inspired air < 320. - patients may be enrolled on this trial while concurrently enrolled on other covid-19 clinical trials.